NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Other Events

ME Staff 8-k
-
0

NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Other Events
Item 8.01. Other Events.

On September15, 2017, Neos Therapeutics,Inc. (the “Company”) issued a press release (the “Press Release”) announcing the approval by the U.S. Food and Drug Administration of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of attention deficit hyperactivity disorder. The Company expects to commence the commercialization of Adzenys ER™ in early 2018. A copy of the Press Release is filed herewith as Exhibit99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits:

Exhibit No.

Description

99.1

Press release dated September15, 2017


Neos Therapeutics, Inc. Exhibit
EX-99.1 2 a17-22152_1ex99d1.htm EX-99.1 Exhibit 99.1     Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older   Neos Therapeutics to launch third medication in ADHD franchise in January 2018   Dallas/Fort Worth,…
To view the full exhibit click here

About NEOS THERAPEUTICS,INC. (NASDAQ:NEOS)

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.